FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.13  |  FHIR Version n/a  User: [n/a]

16251911000001109: Supralip 160mg tablets (Lexon (UK) Ltd) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 04-Jan 2010. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
57298401000001114 Supralip 160mg tablets (Lexon (UK) Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
57298501000001113 Supralip 160mg tablets (Lexon (UK) Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Supralip 160mg tablets (Lexon (UK) Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) Has NHS dm+d (dictionary of medicines and devices) parallel import indicator Parallel Import - supplier (qualifier value) false Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) Has NHS dm+d (dictionary of medicines and devices) parallel import indicator Parallel import true Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) Is a Product containing precisely fenofibrate micronized 160 milligram/1 each conventional release oral tablet true Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) Has active ingredient Fenofibrate micronized false Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) Has manufactured dose form Conventional release oral tablet true Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) Has specific active ingredient Fenofibrate micronized true Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) Has dispensed dose form Tablet true Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Supralip 160mg tablets (Lexon (UK) Ltd) Is a Supralip true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Supralip 160mg tablets (Lexon (UK) Ltd) 30 tablet Has AMP True Supralip 160mg tablets (Lexon (UK) Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start